AQR Capital Management LLC lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 209,265 shares of the medical research company's stock after selling 11,937 shares during the quarter. AQR Capital Management LLC owned about 0.06% of Thermo Fisher Scientific worth $102,357,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in TMO. Advisors Asset Management Inc. lifted its stake in Thermo Fisher Scientific by 2.0% in the first quarter. Advisors Asset Management Inc. now owns 21,031 shares of the medical research company's stock valued at $10,465,000 after buying an additional 419 shares during the period. Amundi raised its position in shares of Thermo Fisher Scientific by 5.9% in the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company's stock valued at $1,426,316,000 after acquiring an additional 168,197 shares during the period. Aprio Wealth Management LLC boosted its stake in Thermo Fisher Scientific by 52.7% during the 1st quarter. Aprio Wealth Management LLC now owns 1,561 shares of the medical research company's stock worth $777,000 after acquiring an additional 539 shares during the last quarter. Federation des caisses Desjardins du Quebec grew its holdings in Thermo Fisher Scientific by 4.7% during the first quarter. Federation des caisses Desjardins du Quebec now owns 76,001 shares of the medical research company's stock valued at $37,826,000 after purchasing an additional 3,415 shares during the period. Finally, Unisphere Establishment raised its holdings in Thermo Fisher Scientific by 14.7% in the first quarter. Unisphere Establishment now owns 1,950,000 shares of the medical research company's stock worth $970,320,000 after purchasing an additional 250,000 shares during the period. Institutional investors own 89.23% of the company's stock.
Insider Transactions at Thermo Fisher Scientific
In other news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,666 shares of company stock worth $13,982,763 in the last 90 days. Corporate insiders own 0.33% of the company's stock.
Thermo Fisher Scientific Stock Up 0.6%
Shares of NYSE TMO traded up $2.71 during midday trading on Friday, reaching $492.20. The company's stock had a trading volume of 1,442,575 shares, compared to its average volume of 1,612,563. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The stock has a 50 day simple moving average of $460.72 and a 200-day simple moving average of $452.89. The stock has a market capitalization of $185.86 billion, a price-to-earnings ratio of 28.47, a PEG ratio of 2.63 and a beta of 0.75. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the prior year, the company posted $5.37 earnings per share. The firm's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.
Thermo Fisher Scientific Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.
Analyst Upgrades and Downgrades
TMO has been the subject of several research analyst reports. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a report on Tuesday. Evercore ISI decreased their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Raymond James Financial reaffirmed an "outperform" rating and set a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Wall Street Zen lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday. Finally, UBS Group raised their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $589.38.
Read Our Latest Research Report on TMO
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Stories

Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report